Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
Cancer Medicine|June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatmentGuido Giordano, Michele Milella, Matteo Landriscina, et al.
British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2020
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino studyAlessandra Raimondi, Massimo Di Maio, Federica Morano, et al.
Oncotarget|May 26, 2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort studyElena Verzoni, Ugo De Giorgi, Lisa Derosa, et al.
Targeted Oncology|December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancerJean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino studyAlessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
ESMO Open|July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancerBeatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
Targeted Oncology|March 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss StudyMaria Di Bartolomeo, Monica Niger, Giuseppe Tirino, et al.
Pageof 25